SLC5A2 and type 2 diabetes mellitus: As well as rodent, a human study has demonstrated that the SGLT2 inhibitor empagliflozin elicited an adaptive increase of energy intake in patients with type 2 diabetes, which caused substantially less weight loss than that expected from the energy dissipated because of glycosuria25.